Lothar Krinke, PhD

Adjunct Assistant Professor

Organization:

West Virginia University School of Medicine

Department:

Department of Neuroscience

Classification:

Adjunct Faculty

Assistant Professor

Organization:

West Virginia University School of Medicine

Department:

Rockefeller Neuroscience Institute (SOM)

Classification:

Adjunct Faculty

• PhD, University at Albany, State University of New York

Wong JK, Mayberg HS, Wang DD, Richardson RM, Halpern CH, Krinke L, Arlotti M, Rossi L, Priori A, Marceglia S, Gilron R, Cavanagh JF, Judy JW, Miocinovic S, Devergnas AD, Sillitoe RV, Cernera S, Oehrn CR, Gunduz A, Goodman WK, Petersen EA, Bronte-Stewart H, Raike RS, Malekmohammadi M, Greene D, Heiden P, Tan H, Volkmann J, Voon V, Li L, Sah P, Coyne T, Silburn PA, Kubu CS, Wexler A, Chandler J, Provenza NR, Heilbronner SR, Luciano MS, Rozell CJ, Fox MD, de Hemptinne C, Henderson JM, Sheth SA, Okun MS. (2022). Proceedings of the 10th annual deep brain stimulation think tank: Advances in cutting edge technologies, artificial intelligence, neuromodulation, neuroethics, interventional psychiatry, and women in neuromodulation. Front Hum Neurosci.;16:1084782. doi: 10.3389/fnhum.2022.1084782. PMID: 36819295; PMCID: PMC9933515.

Wendt, K., Denison, T., Foster, G., Krinke, L., Thomson, A., Wilson, S., & Widge, A. S. (2022). Physiologically informed neuromodulation. Journal of the neurological sciences, 434, 120121. https://doi.org/10.1016/j.jns.2021.120121

Mahoney, J. J., 3rd, Hanlon, C. A., Marshalek, P. J., Rezai, A. R., & Krinke, L. (2020). Transcranial magnetic stimulation, deep brain stimulation, and other forms of neuromodulation for substance use disorders: Review of modalities and implications for treatment. Journal of the neurological sciences, 418, 117149. https://doi.org/10.1016/j.jns.2020.117149

Bari, A. A., Mikell, C. B., Abosch, A., Ben-Haim, S., Buchanan, R. J., Burton, A. W., Carcieri, S., Cosgrove, G. R., D'Haese, P. F., Daskalakis, Z. J., Eskandar, E. N., Gerrard, J. L., Goodman, W. K., Greenberg, B. D., Gross, R. E., Hamani, C., Kiss, Z., Konrad, P., Kopell, B. H., Krinke, L., … Sheth, S. A. (2018). Charting the road forward in psychiatric neurosurgery: proceedings of the 2016 American Society for Stereotactic and Functional Neurosurgery workshop on neuromodulation for psychiatric disorders. Journal of neurology, neurosurgery, and psychiatry, 89(8), 886–896. https://doi.org/10.1136/jnnp-2017-317082

Espay, A. J., Bonato, P., Nahab, F. B., Maetzler, W., Dean, J. M., Klucken, J., Eskofier, B. M., Merola, A., Horak, F., Lang, A. E., Reilmann, R., Giuffrida, J., Nieuwboer, A., Horne, M., Little, M. A., Litvan, I., Simuni, T., Dorsey, E. R., Burack, M. A., Kubota, K., … Movement Disorders Society Task Force on Technology (2016). Technology in Parkinson's disease: Challenges and opportunities. Movement disorders : official journal of the Movement Disorder Society, 31(9), 1272–1282. https://doi.org/10.1002/mds.26642

Krinke, L., Mahoney, M., & Wulff, D. L. (1991). The role of the OOP antisense RNA in coliphage lambda development. Molecular microbiology, 5(5), 1265–1272. https://doi.org/10.1111/j.1365-2958.1991.tb01900.x

Krinke, L., & Wulff, D. L. (1990). RNase III-dependent hydrolysis of lambda cII-O gene mRNA mediated by lambda OOP antisense RNA. Genes & development, 4(12A), 2223–2233. https://doi.org/10.1101/gad.4.12a.2223

Krinke, L., & Wulff, D. L. (1990). The cleavage specificity of RNase III. Nucleic acids research, 18(16), 4809–4815. https://doi.org/10.1093/nar/18.16.4809

Krinke, L., & Wulff, D. L. (1987). OOP RNA, produced from multicopy plasmids, inhibits lambda cII gene expression through an RNase III-dependent mechanism. Genes & development, 1(9), 1005–1013. https://doi.org/10.1101/gad.1.9.1005

My research interests include the broad area of neuromodulation and the molecular biology of gene control.

Currently, I am exploring research related to transcranial magnetic stimulation.  I am conducting some work in navigated TMS and am interested in new indications for TMS such as substance abuse disorder, pain, OCD and dementia.  We need to develop better TMS technology and find ways to use neurophysiological markers to stratify patients that could benefit from TMS and to eventually build a close loop TMS system.

In the past, I have been involved with deep brain stimulation research, therapeutic brain infusion and the use of molecules that inhibit RNA expression in neuronal tissue.

I am currently the CEO, of Magstim Inc. a TMS company.  I also serve on the Board of the UCLA Brain Mapping Medical Research Organization.